RespireRx Pharmaceuticals Inc.
BioTech/Drugs - Glen Rock, NJ, US
RespireRx Pharmaceuticals Inc. Employees
Jeff Margolis
senior vice president, chief financial officer, treasurer, secretary, board of directors member
RespireRx Pharmaceuticals Inc. Senior Management
Jeff Margolis
senior vice president, chief financial officer, treasurer, secretary, board of directors member
RespireRx Pharmaceuticals Inc. Details
RespireRx Pharmaceuticals Inc. is a leader in the discovery and development of medicines for the treatment of psychiatric and neurological disorders, with a focus on treatment options that address conditions affecting millions of people, but for which there are few or poor treatment options, including obstructive sleep apnea ("OSA"), attention deficit hyperactivity disorder ("ADHD"), epilepsy, chronic pain and recovery from spinal cord injury ("SCI"), as well as certain neurological orphan diseases. RespireRx is developing a pipeline of new drug products based on our broad patent portfolios across two distinct drug platforms:Pharmaceutical Cannabinoids. RespireRx is developing dronabinol, ∆-9-tetrahydocannabinol (∆-9-THC), a synthetic version of the naturally occurring substance in the cannabis plant, for the treatment of OSA, a serious respiratory disorder that impacts an estimated 29.4 million people in the USA, linked to increased risk for hypertension, heart failure, depression, and diabetes. There are no approved drug treatments for OSA. In two Phase 2 clinical trials, dronabinol produced statistically significant improvements in OSA.Neuromodulators. RespireRx is developing a portfolio of revolutionary neuromodulator compounds including AMPAkines, proprietary compounds that positively modulate AMPA-type glutamate receptors to promote neuronal function for the treatment of CNS-driven neurobehavioral and cognitive disorders, such as SCI and ADHD where, in a Phase 2 clinical trial, one of our lead ampakines produced rapid, statistically significant improvement in adult patients with ADHD.GABAkines, positive allosteric modulators ("PAMs") of the gamma-amino-butyric acid type A ("GABA-A") receptors, in development for the treatment of epilepsy and other convulsant disorders, as well as chronic pain. Translational studies in human brain tissue obtained from epilepsy patients has validated the anti-epileptic effects of our lead GABAkine.
RespireRx Pharmaceuticals Inc. Technologies
Email Providers
Outlook
CMS
WordPress.org
Other
Mobile Friendly
Hosting
GoDaddy Hosting
Analytics and Tracking
Google Analytics